Home » USA Broker Ratings » Kindred Biosciences – Consensus Indicates Potential 165.8% Upside

Kindred Biosciences – Consensus Indicates Potential 165.8% Upside

Kindred Biosciences found using ticker (KIN) have now 7 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 25 and 9 calculating the mean target price we have 13.93. With the stocks previous close at 5.24 this indicates there is a potential upside of 165.8%. The 50 day moving average now sits at 4.14 and the 200 day MA is 7.58. The market cap for the company is $188m. Find out more information at: http://www.kindredbio.com

Kindred Biosciences, a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats. It is also developing Zimeta IV for the control of fever in horses. In addition, the company develops KIND-016, a monoclonal antibody for the treatment of atopic dermatitis in dogs; KIND-025, a fully canonized and affinity fusion protein targeting interleukin for the treatment of atopic dermatitis in dogs; KIND-032, caninized monoclonal antibody; and KIND-510a, a recombinant feline erythropoietin; and KIND-030, a chimeric and affinity monoclonal antibody targeting canine parvovirus. Further, it is developing KIND-509, an antibody for canine inflammatory bowel disease; KIND-511, an anti-tumor necrosis factor for the treatment of newborn foals; KIND-012, a dipyrone oral gel for the treatment of fever in horses; KIND-014 to treat gastric ulcers in horses; and epoCat, a feline recombinant erythropoietin for the management of anemia in cats. Additionally, it is developing KIND-015 for metabolic syndrome and anti-tumor necrosis factor for sick newborn foals; and interleukin antibodies and canine checkpoint inhibitors. The company was founded in 2012 and is headquartered in Burlingame, California.

Join us on our new LinkedIn page

Follow us on LinkedIn